Zoetis Inc. ZTS
We take great care to ensure that the data presented and summarized in this overview for Zoetis Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ZTS
View all-
Vanguard Group Inc Valley Forge, PA41.4MShares$6.47 Billion0.12% of portfolio
-
Black Rock Inc. New York, NY36.8MShares$5.76 Billion0.15% of portfolio
-
State Street Corp Boston, MA19.8MShares$3.11 Billion0.13% of portfolio
-
State Farm Mutual Automobile Insurance CO Bloomington, IL16MShares$2.51 Billion2.4% of portfolio
-
Morgan Stanley New York, NY11.8MShares$1.85 Billion0.14% of portfolio
-
Alliancebernstein L.P. New York, NY11.8MShares$1.85 Billion0.69% of portfolio
-
Bank Of America Corp Charlotte, NC11.5MShares$1.8 Billion0.16% of portfolio
-
Geode Capital Management, LLC Boston, MA10.6MShares$1.66 Billion0.14% of portfolio
-
Polen Capital Polen Capital Management LLC | Boca Raton, Fl7.48MShares$1.17 Billion3.29% of portfolio
-
Wellington Management Group LLP Boston, MA6.96MShares$1.09 Billion0.21% of portfolio
Latest Institutional Activity in ZTS
Top Purchases
Top Sells
About ZTS
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
Insider Transactions at ZTS
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Feb 14
2025
|
Gregory Norden Director |
SELL
Bona fide gift
|
Direct |
1,843
-100.0%
|
-
|
Feb 11
2025
|
Roxanne Lagano Executive Vice President |
SELL
Open market or private sale
|
Direct |
326
-1.98%
|
$55,746
$171.18 P/Share
|
Feb 08
2025
|
Robert J Polzer Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
628
-6.14%
|
$107,388
$171.43 P/Share
|
Feb 08
2025
|
Robert J Polzer Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
2,086
+16.84%
|
-
|
Feb 08
2025
|
Robert W Scully Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,225
+23.65%
|
-
|
Feb 08
2025
|
Michael B Mccallister Director |
SELL
Other acquisition or disposition
|
Direct |
313
-14.59%
|
$53,523
$171.43 P/Share
|
Feb 08
2025
|
Michael B Mccallister Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,225
+36.34%
|
-
|
Feb 08
2025
|
Roxanne Lagano Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
690
-2.09%
|
$117,990
$171.43 P/Share
|
Feb 08
2025
|
Roxanne Lagano Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
2,001
+5.67%
|
-
|
Feb 08
2025
|
Willie M Reed Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,225
+8.95%
|
-
|
Feb 08
2025
|
Kristin C Peck Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,197
-4.77%
|
$1,572,687
$171.43 P/Share
|
Feb 08
2025
|
Kristin C Peck Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,433
+9.46%
|
-
|
Feb 08
2025
|
Antoinette Renee Leatherberry Director |
SELL
Other acquisition or disposition
|
Direct |
308
-7.04%
|
$52,668
$171.43 P/Share
|
Feb 08
2025
|
Antoinette Renee Leatherberry Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,225
+21.88%
|
-
|
Feb 08
2025
|
Louise M Parent Director |
SELL
Other acquisition or disposition
|
Direct |
466
-2.96%
|
$79,686
$171.43 P/Share
|
Feb 08
2025
|
Louise M Parent Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,225
+7.23%
|
-
|
Feb 08
2025
|
Gregory Norden Director |
SELL
Other acquisition or disposition
|
Direct |
308
-14.32%
|
$52,668
$171.43 P/Share
|
Feb 08
2025
|
Gregory Norden Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,225
+36.29%
|
-
|
Feb 08
2025
|
Astorga Jeannette Ferran Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
277
-11.09%
|
$47,367
$171.43 P/Share
|
Feb 08
2025
|
Astorga Jeannette Ferran Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
691
+21.47%
|
-
|
Last 12 Months Summary
Exercise of conversion of derivative security | 107K shares |
---|
Other acquisition or disposition | 3.74K shares |
---|---|
Bona fide gift | 20.9K shares |
Payment of exercise price or tax liability | 30.5K shares |
Open market or private sale | 20.9K shares |